EU/3/16/1801

About

On 12 December 2016, orphan designation (EU/3/16/1801) was granted by the European Commission to MediciNova (Europe) Limited, United Kingdom, for ibudilast for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
Ibudilast
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of first decision
12/12/2016
Outcome
Positive
EU designation number
EU/3/16/1801

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

MediciNova (Europe) Limited
12 Fetter Lane
London EC4A 1JP
United Kingdom
Tel. +44 (0)20 7905 6332
E-mail: inquiries@medicinova.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating